Physician profile
Kit S Mays
NPI 1104993773
$480.62
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $111.64 | 2019 | |
| Boston Scientific Corporation | $93.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.94 | 2019 | |
| Scilex Pharmaceuticals INC. | $57.41 | 2019 | |
| Supernus Pharmaceuticals, INC. | $53.17 | 2019 | |
| Amgen INC. | $31.94 | 2019 | |
| Vanda Pharmaceuticals INC. | $26.55 | 2019 | |
| Upsher-Smith Laboratories LLC | $17.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.07 | 2019 | |
| Zyla Life Sciences, INC. | $15.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kit Mays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.